Pharmacogenetics of antidepressants
Up to 60% of depressed patients do not respond completely to antidepressants (AD) and up to 30% do not respond at all. Genetic factors contribute for about 50% of the AD response. During the recent years the possible influence of a set of candidate genes as genetic predictors of AD response efficacy...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2011-02-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/Journal/10.3389/fphar.2011.00006/full |
id |
doaj-ecf60e291d1345ff9a50b20996fc98b1 |
---|---|
record_format |
Article |
spelling |
doaj-ecf60e291d1345ff9a50b20996fc98b12020-11-24T23:09:46ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122011-02-01210.3389/fphar.2011.000069134Pharmacogenetics of antidepressantsConcetta eCrisafulli0Chiara eFabbri1Stefano ePorcelli2Antonio eDrago3Edoardo eSpina4Diana eDe Ronchi5Alessandro eSerretti6University of MessinaUniversity of BolognaUniversity of BolognaUniversity of BolognaUniversity of MessinaUniversity of BolognaUniversity of BolognaUp to 60% of depressed patients do not respond completely to antidepressants (AD) and up to 30% do not respond at all. Genetic factors contribute for about 50% of the AD response. During the recent years the possible influence of a set of candidate genes as genetic predictors of AD response efficacy was investigated by us and others. They include the cytochrome P450 (CYP) superfamily, the P-glycoprotein (ABCB1), the tryptophan hydroxylase (TPH), the catechol-O-methyltransferase (COMT), the monoamine oxidase A (MAOA), the serotonin transporter (5-HTTLPR), the norepinephrine transporter (NET), the dopamine transporter (DAT), variants in the 5HT1A, 2A , 3A, 3B and 6 receptors, adrenoreceptor beta-1 (ADRB1) and alpha-2 (ADRA2A), the dopamine receptors (D2), the G-protein beta3-subunit (GNB3), the corticotropin releasing hormone (CRH) receptors (CRHR1 and CRHR2), the glucocorticoid receptors (GR), the c-AMP response-element binding (CREB) and the brain-derived neurotrophic factor (BDNF). Marginal associations were reported for angiotensin I converting enzyme (ACE), circadian locomoter output cycles kaput protein (CLOCK), glutamatergic system, nitric oxide synthase (NOS) and interleukin 1-beta (IL-1beta) gene. In conclusion, gene variants seem to influence human behavior, liability to disorders and treatment response. Nonetheless, gene x enviroment interactions have been hypothesized to modulate several of these effects.http://journal.frontiersin.org/Journal/10.3389/fphar.2011.00006/fullDepressionPharmacogeneticsgeneSNPAntidepressants |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Concetta eCrisafulli Chiara eFabbri Stefano ePorcelli Antonio eDrago Edoardo eSpina Diana eDe Ronchi Alessandro eSerretti |
spellingShingle |
Concetta eCrisafulli Chiara eFabbri Stefano ePorcelli Antonio eDrago Edoardo eSpina Diana eDe Ronchi Alessandro eSerretti Pharmacogenetics of antidepressants Frontiers in Pharmacology Depression Pharmacogenetics gene SNP Antidepressants |
author_facet |
Concetta eCrisafulli Chiara eFabbri Stefano ePorcelli Antonio eDrago Edoardo eSpina Diana eDe Ronchi Alessandro eSerretti |
author_sort |
Concetta eCrisafulli |
title |
Pharmacogenetics of antidepressants |
title_short |
Pharmacogenetics of antidepressants |
title_full |
Pharmacogenetics of antidepressants |
title_fullStr |
Pharmacogenetics of antidepressants |
title_full_unstemmed |
Pharmacogenetics of antidepressants |
title_sort |
pharmacogenetics of antidepressants |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Pharmacology |
issn |
1663-9812 |
publishDate |
2011-02-01 |
description |
Up to 60% of depressed patients do not respond completely to antidepressants (AD) and up to 30% do not respond at all. Genetic factors contribute for about 50% of the AD response. During the recent years the possible influence of a set of candidate genes as genetic predictors of AD response efficacy was investigated by us and others. They include the cytochrome P450 (CYP) superfamily, the P-glycoprotein (ABCB1), the tryptophan hydroxylase (TPH), the catechol-O-methyltransferase (COMT), the monoamine oxidase A (MAOA), the serotonin transporter (5-HTTLPR), the norepinephrine transporter (NET), the dopamine transporter (DAT), variants in the 5HT1A, 2A , 3A, 3B and 6 receptors, adrenoreceptor beta-1 (ADRB1) and alpha-2 (ADRA2A), the dopamine receptors (D2), the G-protein beta3-subunit (GNB3), the corticotropin releasing hormone (CRH) receptors (CRHR1 and CRHR2), the glucocorticoid receptors (GR), the c-AMP response-element binding (CREB) and the brain-derived neurotrophic factor (BDNF). Marginal associations were reported for angiotensin I converting enzyme (ACE), circadian locomoter output cycles kaput protein (CLOCK), glutamatergic system, nitric oxide synthase (NOS) and interleukin 1-beta (IL-1beta) gene. In conclusion, gene variants seem to influence human behavior, liability to disorders and treatment response. Nonetheless, gene x enviroment interactions have been hypothesized to modulate several of these effects. |
topic |
Depression Pharmacogenetics gene SNP Antidepressants |
url |
http://journal.frontiersin.org/Journal/10.3389/fphar.2011.00006/full |
work_keys_str_mv |
AT concettaecrisafulli pharmacogeneticsofantidepressants AT chiaraefabbri pharmacogeneticsofantidepressants AT stefanoeporcelli pharmacogeneticsofantidepressants AT antonioedrago pharmacogeneticsofantidepressants AT edoardoespina pharmacogeneticsofantidepressants AT dianaederonchi pharmacogeneticsofantidepressants AT alessandroeserretti pharmacogeneticsofantidepressants |
_version_ |
1725609489871142912 |